IN MODERATE TO SEVERE PLAQUE PsO
Patients saw clearer skin at Week 161,2
VOYAGE 1: Major secondary endpoints at Weeks 16, 24, and 48 (NRI)*

The same patients may not have responded at each time point.
VOYAGE co-primary endpoints at Week 16 (NRI)1,2:
VOYAGE 1—PASI 90: TREMFYA® 73% (241/329), placebo 3% (5/174) (P<0.001). IGA 0/1: TREMFYA® 85% (280/329), placebo 7% (12/174) (P<0.001). VOYAGE 2—PASI 90: TREMFYA® 70% (347/496), placebo 2% (6/248) (P<0.001). IGA 0/1: TREMFYA® 84% (417/496), placebo 8% (21/248) (P<0.001).
Psoriasis Symptoms and Signs Diary (Week 16): Greater improvements in symptoms of psoriasis (itch, pain, stinging, burning, and skin tightness).2
VOYAGE 2: Major secondary endpoint at Week 16 (NRI)1,2*†
- 64% (102/160) of patients receiving TREMFYA® achieved PASI 90 vs 42% (34/81) of patients receiving Humira®
VOYAGE 2: Major secondary endpoint at Week 24 (NRI)1,2*‡
- 71% (113/160) of patients receiving TREMFYA® achieved PASI 90 vs 51% (41/81) of patients receiving Humira®
*Results from North American sites only, which used US-licensed Humira®.
†P<0.001 vs Humira®.
‡P=0.003 vs Humira®.
Humira is a registered trademark of Abbvie Biotechnology Ltd. Corporation.
NRI=nonresponder imputation.
References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
The majority of patients saw clearer skin with TREMFYA®1,2
VOYAGE 1: Major secondary endpoints at Weeks 16, 24, and 48 (NRI)*

The same patients may not have responded at each time point.
VOYAGE co-primary endpoints at Week 16 (NRI)1,2:
VOYAGE 1—PASI 90: TREMFYA® 73% (241/329), placebo 3% (5/174) (P<0.001). IGA 0/1: TREMFYA® 85% (280/329), placebo 7% (12/174) (P<0.001). VOYAGE 2—PASI 90: TREMFYA® 70% (347/496), placebo 2% (6/248) (P<0.001). IGA 0/1: TREMFYA® 84% (417/496), placebo 8% (21/248) (P<0.001).
Psoriasis Symptoms and Signs Diary (Week 16): Greater improvements in symptoms of psoriasis (itch, pain, stinging, burning, and skin tightness).2
VOYAGE 2: Major secondary endpoint at Week 16 (NRI)1,2*‡
- 74% (119/160) of patients receiving TREMFYA® achieved IGA 0/1 vs 62% (50/81) of patients receiving Humira®
VOYAGE 2: Major secondary endpoint at Week 24 (NRI)1,2*§
- 74% (119/160) of patients receiving TREMFYA® achieved IGA 0/1 vs 57% (46/81) of patients receiving Humira®
Humira is a registered trademark of Abbvie Biotechnology Ltd. Corporation.
Nonresponder imputation (NRI) methods were used for analysis.
*Results from North American sites only, which used US-licensed Humira®.
†P<0.001 vs Humira®.
‡P<0.027 vs Humira®.
§P=0.005 vs Humira®.
References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
No footer content content fetched
Last updated 04/24
No footer links content fetched


